Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-11

Study Completion Date

2019-04-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer

NCT03129698

Apatinib in Maintenance Treatment

UNKNOWN PHASE2

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

NCT03389087

Small Cell Lung Cancer

UNKNOWN PHASE2

Apatinib in Advanced Non-squamous，NSCLC

NCT03376191

Non-squamous Non-Small Cell Lung Cancer

UNKNOWN

Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

NCT03359018

Progression-free Survival Overall Survival Clinical Benefit Rate +1 more

COMPLETED PHASE2

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

NCT03144856

Biliary Tract Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The treatment of bone and soft tissue sarcomas are usually surgery and chemotherapy,advanced cases cannot be removed through surgical method for multiple metastasis,advanced cases Most advanced cases with chemotherapy is given priority to, but the effect is not ideal.Apatinib main through inhibit VEGFR to give play to Anti-angiogenesis effect to treatment of malignant tumor.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteosarcoma, Advanced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apatinib

Apatinib 500mg/d from day 1 to day 28, repeated every 28 days until progressive Disease(PD) .

Group Type EXPERIMENTAL

Apatinib

Intervention Type DRUG

Apatinib 500mg,po,qd,medicine to disease progression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apatinib

Apatinib 500mg,po,qd,medicine to disease progression.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject joined the study of his or her own free will , signed informed consent;
2. Subject that diagnosed with advanced osteosarcoma by pathology and first-line treatment failure, at least have one measurable lesion ; Or confirmed by the pathology of advanced soft tissue sarcomas, at least have one measurable lesion,main include Synovial sarcoma、 Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、 Fibrosarcoma、Clear cell sarcoma、Epithelioid sarcoma、Malignant peripheral nerve sheath tumor、Undifferentiatedsarcoma、 Rhabdomyosarcoma、chondrosarcoma、Osteosarcoma、Dermato- fibrosarcoma protuberans、GIST、Primitiveneuroectodermal tumor、Inflammatory myofibroblastic tumor、Malignant mesothelioma； 3）Within the past 6 months, Subject using at least one chemotherapy regimens (including anthracycline-based) failured (except gland alveolar soft tissue sarcoma); 4）18 to 70 years (including 18 and 70 ), men and women there is no limited. 5）ECOG PS score: 0 \~ 1; 6）Estimated survival period more than 3 months; 7）Main organs function within 7 days before the treatment, meet the following criteria:

1. Blood routine examination standard( without blood transfusion condition in 14 days) :HB≥90g/L;②ANC≥1.5×109/L;③PLT≥80×109/L
2. Blood biochemical examination must meet the following criteria:

① TBIL≤1.5ULN ；②ALT and AST≤2.5ULN，if With hepatic metastatic carcinoma，ALT and AST≤5ULN；③Cr≤1.5ULN或CCr≥60ml/min；
3. Doppler ultrasound assessment: LVEF normal or low limit (50%).

Exclusion Criteria

\- 1）Subject with hypertension, and after antihypertensive drug therapy can't to the normal range (systolic blood pressure \> 140 mmHg, diastolic blood pressure \> 90 mmHg), Ⅱ or higher level of coronary heart disease, arrhythmia (include QTc prolonging, male \> 450 ms, female \> 470 ms) and cardiac insufficiency; 2）Subject used targeted therapy of vascular endothelial growth inhibitor drug previous, include Sunitinib, Sorafenib ,bevacizumab, imatinib and so on.

3）With other malignant tumor before or at the same time, but except the cured skin basal cell carcinoma and carcinoma in situ of cervix.

4）Subject accepted anticancer therapy before with NCI CTCAE classification \> 1 grade toxicity reaction.

5）Has multi-factors that effect of oral drug absorption(, such as unable to swallow, nausea or vomiting, chronic diarrhea and intestinal obstruction, etc.); 6）Special note: subject with gastrointestinal bleeding risk can't enrolled the study, include: (1) there are active peptic ulcer lesions, and defecate occult blood (+ +);(2)Subject with medical history include Melena、hematemesis in three months;(3) Subject must be of gastroscopy with defecate occult blood, clear whether deposit organic gastrointestinal tract diseases; 7）Subject with coagulant function abnormality (INR \> 1.5 x ULN, APTT \> 1.5 x ULN), bleeding tendency; 8）Didn't heal wounds for a long time or fracture. 9）Subject with active bleeding or within 30 days after Major surgery. 10）Intracranial metastasis; 11）Pregnant or lactating women; 12）cell toxic drug therapy, radiation therapy 3 weeks after treatment; Once took two or more targeted drugs, or once took other targeted drugs 3 months before enrollment.

13）Suffered from other malignant tumor for the past three years. 14）Investigator considered that there may be exist any situation that can damage subject or result in subject can't meet or carry out Investigator requests.

15）huge transfer/recurrent lesions(tumor size greater than 5 cm). 16）malignant pleuraleffusion or peritoneal effusion, caused NCI CTCAE grading more than 2 levels of breathing difficulties; Description: oversized tumor load often indicates poor blood supply, lead to drug unable to effectively into the tumor, in order to accurately assess the treatment effects apatinib to the soft tissue sarcomas, Our study do not accept with huge transfer recurrent focal (tumor diameter greater than 5 cm) of the patients into groups temporarily .

17）Allergy to any ingredient about apatinibshould be ruled out; 18）Subject with severe liver and renal failure (level 4) should be ruled out; 19）Subject has a history of psychiatric drugs abuse and can't quit or have a mental disorder; 20）According to the investigator's judgment, subject who has concomitant diseases that serious to endanger the safety or impact subject to complete the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No